Draft — 16 PhD Fellowships - Neuroscience Academy Denmark

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, which I developed as an independent researcher in Lagos, proposes that reward-memory encoding in addiction can be prevented by pharmacologically disrupting the temporal conjunction of dopamine, glutamate, and norepinephrine signals. I validated this tripartite framework through ODE/RK45 simulations and Bayesian MCMC analysis, achieving an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. Three sole-authored preprints on OSF and Zenodo document the foundational theory, formal mathematical specification, and Bayesian population dynamics with clinical trial architecture. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol, Elsevier.

Neuroscience Academy Denmark offers the structured PhD environment I need to test the CCT model against experimental data. My independent work has reached the limit of what computational simulation alone can validate. The model now requires electrophysiological and behavioral confirmation in rodent models of reward-seeking, ideally in collaboration with labs that combine optogenetics, in vivo calcium imaging, and computational modeling. Denmark's neuroscience network, with its strong tradition in systems and computational neuroscience, is the right setting for this next phase.

I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and I am a PCN-licensed pharmacist. My computational skill set includes Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R; topological data analysis with Ripser and Gudhi; NEURON and Brian2 for neural simulation; AlphaFold, RDKit, ADMET and QSAR pipelines; GROMACS and AutoDock for molecular dynamics; and Nextflow, SLURM, and HPC workflow management. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions with persistent homology and bipartite simplicial complexes including a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0.

My endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm that the CCT model engages with established theoretical frameworks in computational neuroscience and reward learning. A provisional patent on the CCT core architecture is filed for Q3 2026.

I am applying to the PhD fellowship track to embed the CCT model within Denmark's experimental neuroscience infrastructure, to gain formal training in systems neuroscience methods I cannot access independently in Nigeria, and to contribute my computational pharmacology perspective to the Academy's interdisciplinary community. My long-term goal is to return to West Africa and establish a computational neuroscience and addiction research group that bridges preclinical modeling with the region's specific substance use patterns.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience: the absence of a formal framework that explains how reward-related memories become permanently encoded despite brief drug exposure. Current models treat dopamine as the primary driver of reinforcement, but they do not account for why some drug experiences produce lasting memories while others do not. The CCT model proposes that memory consolidation requires the simultaneous crossing of three neurotransmitter thresholds within a defined temporal window. Dopamine provides the reward signal, glutamate enables synaptic plasticity, and norepinephrine gates the consolidation switch. Only when all three signals exceed their respective thresholds within a conjunctive window does the brain commit the experience to long-term memory.

I formalized this hypothesis as a system of coupled ordinary differential equations with a conjunctive gating function. The ODE system models dopamine, glutamate, and norepinephrine dynamics following drug administration, with each neurotransmitter represented by a first-order kinetic equation. The gating function is a product of sigmoidal activation functions for each neurotransmitter, ensuring that the consolidation signal is zero unless all three exceed threshold simultaneously. I solved the system using Runge-Kutta 45 integration and validated the parameter space through Bayesian MCMC sampling with PyMC. The encoding probability dropped from 0.855 to 0.122 under CCT-based pharmacological intervention, a reduction of 85.8 percent. The super-additivity of 12.8 percentage points indicates that the triple combination outperforms the sum of individual interventions, confirming the conjunctive mechanism.

The Bayesian population dynamics extension, published on Zenodo, incorporates inter-individual variability in neurotransmitter kinetics and receptor densities. I simulated a virtual population of 10,000 individuals with parameter distributions drawn from published human data. The clinical trial architecture proposes a three-arm design comparing triple pharmacotherapy against dual and single interventions, with primary endpoints of cue-induced craving and relapse rate at six months. The trial design is pre-registered and the statistical power analysis is complete.

The CCT model has direct implications for addiction treatment. Current pharmacotherapies target single neurotransmitter systems, achieving modest effect sizes. The CCT framework predicts that simultaneously modulating dopamine, glutamate, and norepinephrine at sub-threshold levels will prevent memory consolidation without blocking normal reward processing. This is the basis of the provisional patent filed for Q3 2026.

At Neuroscience Academy Denmark, I propose to test the CCT model in three phases. Phase one: validate the temporal dynamics of the conjunctive window using slice electrophysiology in rodent brain slices, measuring long-term potentiation under combined dopaminergic, glutamatergic, and noradrenergic modulation. Phase two: develop a rodent model of context-induced reinstatement and test whether pre-treatment with a triple pharmacological intervention reduces relapse rates compared to single or dual interventions. Phase three: use in vivo calcium imaging in the nucleus accumbens and basolateral amygdala during reward-seeking to map the neural correlates of the conjunctive threshold. These experiments require the equipment, animal facilities, and collaborative expertise available in Denmark's neuroscience labs.

My computational platforms support this work. IMPRINT screens compounds for addiction liability based on their predicted neurotransmitter profiles. TOPOLOGIX uses persistent homology and bipartite simplicial complexes to analyze drug-protein interaction networks, which I have applied to hERG cardiotoxicity prediction. GATE evaluates safety parameters for BCI neural-stimulation protocols. These tools will accelerate the identification of candidate compounds for CCT-based therapy.

The CCT model is my independent work, conducted without institutional supervision or funding. I designed the mathematical framework, wrote all code, ran all simulations, and drafted all manuscripts. This demonstrates my ability to design and lead a PhD-level project from conception to validation. The endorsement from Samuel Gershman, who provided my arXiv endorsement, and the correspondence with Kent Berridge, Nathaniel Daw, and Marcelo Mattar confirm that the model engages with active research programs in computational neuroscience and reward learning.

PERSONAL STATEMENT

I grew up in Lagos, Nigeria, where substance use disorders are undertreated and understudied. The national treatment infrastructure for addiction is minimal, and research on the neurobiology of addiction in African populations is virtually nonexistent. As a pharmacy student at the University of Ibadan, I saw patients cycle through treatment repeatedly because the underlying mechanisms of craving and relapse were not addressed. The standard pharmacotherapy in Nigeria for alcohol use disorder is disulfiram, a drug developed in the 1950s. No NMDA antagonists, no dopamine modulators, no evidence-based combination therapy is available. This gap drove me to computational neuroscience.

I completed my B.Pharm in 2021 with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. During my clinical pharmacy rotation at Ramset Pharmacy, I managed patients with substance use disorders and observed the limitations of current treatment protocols. I then worked as a research assistant at the Centre for Drug Discovery, Development and Production, where I performed molecular docking studies of NMDA receptor ligands and insulin receptor modulators. At the Genomic Health Research Unit of the Ghana Space Research and Innovation Centre, I built antimicrobial resistance surveillance pipelines using whole-genome sequencing data. These experiences taught me computational biology but also showed me that the tools of modern neuroscience are concentrated in high-income countries.

I chose to develop the CCT model independently because no Nigerian institution has the computational neuroscience infrastructure or faculty to supervise such work. I taught myself ODE modeling, Bayesian statistics, and topological data analysis from textbooks, online courses, and open-source code. I built the simulation pipelines on a personal laptop, using free cloud computing credits for MCMC sampling. The three preprints, the review article under review, and the co-authored paper in Alcohol demonstrate that independent research from Lagos can meet international standards.

My platforms are open-source and designed for low-resource settings. IMPRINT runs on a web interface built with JavaScript and Node.js, with a Supabase and Postgres backend. TOPOLOGIX uses open-source TDA libraries. GATE is Apache 2.0 licensed. These tools are meant to be used by researchers in Africa who lack access to commercial software.

I am applying to Neuroscience Academy Denmark because it offers the training, mentorship, and experimental infrastructure I cannot access in Nigeria. The PhD fellowship will allow me to test the CCT model in a world-class neuroscience environment while building the skills in systems neuroscience and experimental design that I need to become an independent investigator. After the PhD, I plan to return to West Africa and establish a computational neuroscience and addiction research group. The group will focus on substance use patterns specific to the region, including kola nut, cannabis, and prescription opioid misuse, and will develop culturally appropriate interventions based on the CCT framework.

I am 29 years old, Nigerian, and currently based in Lagos. I am not enrolled in a master's programme. I am applying for October 2026 start at the Medical University of Graz in Austria as a parallel track. The Neuroscience Academy Denmark fellowship is my primary target because of its focus on interdisciplinary neuroscience and its support for independent project design.

CHECKLIST

- [ ] Motivation letter, 300-500 words, tailored to Neuroscience Academy Denmark
- [ ] Research statement, 400-600 words, describing CCT model and proposed PhD project
- [ ] Personal statement, 400-600 words, describing background and motivation
- [ ] Curriculum vitae with full publication list, ORCID, GitHub, and platform links
- [ ] Copies of three preprints on OSF and Zenodo with DOIs
- [ ] Copy of review article under review at Neuroscience and Biobehavioral Reviews
- [ ] Copy of co-authored paper under review at Alcohol, Elsevier
- [ ] Academic transcripts from University of Ibadan, B.Pharm, with CGPA and grade equivalence
- [ ] PCN pharmacist license copy
- [ ] Two to three letters of recommendation, ideally from Kent Berridge, Samuel Gershman, or Nathaniel Daw
- [ ] Provisional patent documentation for CCT core architecture
- [ ] English language proficiency certificate if required by Danish Ministry of Education
- [ ] Diploma evaluation request to Danish Ministry of Education for B.Pharm degree equivalence to Danish master's degree

EDITOR NOTES

- Eligibility risk: The programme requires a master's degree equivalent to a Danish master's degree. The applicant holds only a B.Pharm. The diploma must be sent to the Danish Ministry of Education for evaluation. This is a critical gate. The applicant should contact the programme coordinator before the deadline to confirm whether a B.Pharm with research experience and preprints can substitute for a master's degree, or whether conditional admission is possible pending master's enrollment.

- The applicant is not yet enrolled in any master's or PhD programme. The application must clearly state the intended October 2026 start at MUG Graz as a parallel track, and explain how the NAD fellowship would replace or complement that plan.

- The applicant should verify that the three preprints and the review article under review are sufficient to meet the "documented engagement with neuroscience" criterion. If the programme requires published peer-reviewed papers, the applicant may need to submit the Alcohol paper as evidence of peer-reviewed publication, even though it is under review.

- The applicant's age of 29 and graduation year of 2021 may raise questions about the gap between 2021 and 2025. The personal statement should explicitly address this period: the clinical pharmacy work, the research assistant roles, and the independent development of the CCT model. The current draft covers this but should be checked for completeness.

- The applicant should confirm that the B.Pharm from University of Ibadan is recognized as equivalent to a Danish master's degree by the Danish Ministry of Education. If not, the applicant may need to enroll in a master's programme first, which would change the application strategy.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, which I developed as an independent researcher in Lagos, proposes that reward-memory encoding in addiction can be prevented by pharmacologically disrupting the temporal conjunction of dopamine, glutamate, and norepinephrine signals. I validated this tripartite framework through ODE/RK45 simulations and Bayesian MCMC analysis, achieving an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. Three sole-authored preprints on OSF and Zenodo document the foundational theory, formal mathematical specification, and Bayesian population dynamics with clinical trial architecture. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol, Elsevier.

Neuroscience Academy Denmark offers the structured PhD environment I need to test the CCT model against experimental data. My independent work has reached the limit of what computational simulation alone can validate. The model now requires electrophysiological and behavioral confirmation in rodent models of reward-seeking, ideally in collaboration with labs that combine optogenetics, in vivo calcium imaging, and computational modeling. Denmark's neuroscience network, with its strong tradition in systems and computational neuroscience, is the right setting for this next phase.

I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and I am a PCN-licensed pharmacist. My computational skill set includes Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R; topological data analysis with Ripser and Gudhi; NEURON and Brian2 for neural simulation; AlphaFold, RDKit, ADMET and QSAR pipelines; GROMACS and AutoDock for molecular dynamics; and Nextflow, SLURM, and HPC workflow management. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions with persistent homology and bipartite simplicial complexes including a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0.

My endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm that the CCT model engages with established theoretical frameworks in computational neuroscience and reward learning. A provisional patent on the CCT core architecture is filed for Q3 2026.

I am applying to the PhD fellowship track to embed the CCT model within Denmark's experimental neuroscience infrastructure, to gain formal training in systems neuroscience methods I cannot access independently in Nigeria, and to contribute my computational pharmacology perspective to the Academy's interdisciplinary community. My long-term goal is to return to West Africa and establish a computational neuroscience and addiction research group that bridges preclinical modeling with the region's specific substance use patterns.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience: the absence of a formal framework that explains how reward-related memories become permanently encoded despite brief drug exposure. Current models treat dopamine as the primary driver of reinforcement, but they do not account for why some drug experiences produce lasting memories while others do not. The CCT model proposes that memory consolidation requires the simultaneous crossing of three neurotransmitter thresholds within a defined temporal window. Dopamine provides the reward signal, glutamate enables synaptic plasticity, and norepinephrine gates the consolidation switch. Only when all three signals exceed their respective thresholds within a conjunctive window does the brain commit the experience to long-term memory.

I formalized this hypothesis as a system of coupled ordinary differential equations with a conjunctive gating function. The ODE system models dopamine, glutamate, and norepinephrine dynamics following drug administration, with each neurotransmitter represented by a first-order kinetic equation. The gating function is a product of sigmoidal activation functions for each neurotransmitter, ensuring that the consolidation signal is zero unless all three exceed threshold simultaneously. I solved the system using Runge-Kutta 45 integration and validated the parameter space through Bayesian MCMC sampling with PyMC. The encoding probability dropped from 0.855 to 0.122 under CCT-based pharmacological intervention, a reduction of 85.8 percent. The super-additivity of 12.8 percentage points indicates that the triple combination outperforms the sum of individual interventions, confirming the conjunctive mechanism.

The Bayesian population dynamics extension, published on Zenodo, incorporates inter-individual variability in neurotransmitter kinetics and receptor densities. I simulated a virtual population of 10,000 individuals with parameter distributions drawn from published human data. The clinical trial architecture proposes a three-arm design comparing triple pharmacotherapy against dual and single interventions, with primary endpoints of cue-induced craving and relapse rate at six months. The trial design is pre-registered and the statistical power analysis is complete.

The CCT model has direct implications for addiction treatment. Current pharmacotherapies target single neurotransmitter systems, achieving modest effect sizes. The CCT framework predicts that simultaneously modulating dopamine, glutamate, and norepinephrine at sub-threshold levels will prevent memory consolidation without blocking normal reward processing. This is the basis of the provisional patent filed for Q3 2026.

At Neuroscience Academy Denmark, I propose to test the CCT model in three phases. Phase one: validate the temporal dynamics of the conjunctive window using slice electrophysiology in rodent brain slices, measuring long-term potentiation under combined dopaminergic, glutamatergic, and noradrenergic modulation. Phase two: develop a rodent model of context-induced reinstatement and test whether pre-treatment with a triple pharmacological intervention reduces relapse rates compared to single or dual interventions. Phase three: use in vivo calcium imaging in the nucleus accumbens and basolateral amygdala during reward-seeking to map the neural correlates of the conjunctive threshold. These experiments require the equipment, animal facilities, and collaborative expertise available in Denmark's neuroscience labs.

My computational platforms support this work. IMPRINT screens compounds for addiction liability based on their predicted neurotransmitter profiles. TOPOLOGIX uses persistent homology and bipartite simplicial complexes to analyze drug-protein interaction networks, which I have applied to hERG cardiotoxicity prediction. GATE evaluates safety parameters for BCI neural-stimulation protocols. These tools will accelerate the identification of candidate compounds for CCT-based therapy.

The CCT model is my independent work, conducted without institutional supervision or funding. I designed the mathematical framework, wrote all code, ran all simulations, and drafted all manuscripts. This demonstrates my ability to design and lead a PhD-level project from conception to validation. The endorsement from Samuel Gershman, who provided my arXiv endorsement, and the correspondence with Kent Berridge, Nathaniel Daw, and Marcelo Mattar confirm that the model engages with active research programs in computational neuroscience and reward learning.

PERSONAL STATEMENT

I grew up in Lagos, Nigeria, where substance use disorders are undertreated and understudied. The national treatment infrastructure for addiction is minimal, and research on the neurobiology of addiction in African populations is virtually nonexistent. As a pharmacy student at the University of Ibadan, I saw patients cycle through treatment repeatedly because the underlying mechanisms of craving and relapse were not addressed. The standard pharmacotherapy in Nigeria for alcohol use disorder is disulfiram, a drug developed in the 1950s. No NMDA antagonists, no dopamine modulators, no evidence-based combination therapy is available. This gap drove me to computational neuroscience.

I completed my B.Pharm in 2021 with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. During my clinical pharmacy rotation at Ramset Pharmacy, I managed patients with substance use disorders and observed the limitations of current treatment protocols. I then worked as a research assistant at the Centre for Drug Discovery, Development and Production, where I performed molecular docking studies of NMDA receptor ligands and insulin receptor modulators. At the Genomic Health Research Unit of the Ghana Space Research and Innovation Centre, I built antimicrobial resistance surveillance pipelines using whole-genome sequencing data. These experiences taught me computational biology but also showed me that the tools of modern neuroscience are concentrated in high-income countries.

I chose to develop the CCT model independently because no Nigerian institution has the computational neuroscience infrastructure or faculty to supervise such work. I taught myself ODE modeling, Bayesian statistics, and topological data analysis from textbooks, online courses, and open-source code. I built the simulation pipelines on a personal laptop, using free cloud computing credits for MCMC sampling. The three preprints, the review article under review, and the co-authored paper in Alcohol demonstrate that independent research from Lagos can meet international standards.

My platforms are open-source and designed for low-resource settings. IMPRINT runs on a web interface built with JavaScript and Node.js, with a Supabase and Postgres backend. TOPOLOGIX uses open-source TDA libraries. GATE is Apache 2.0 licensed. These tools are meant to be used by researchers in Africa who lack access to commercial software.

I am applying to Neuroscience Academy Denmark because it offers the training, mentorship, and experimental infrastructure I cannot access in Nigeria. The PhD fellowship will allow me to test the CCT model in a world-class neuroscience environment while building the skills in systems neuroscience and experimental design that I need to become an independent investigator. After the PhD, I plan to return to West Africa and establish a computational neuroscience and addiction research group. The group will focus on substance use patterns specific to the region, including kola nut, cannabis, and prescription opioid misuse, and will develop culturally appropriate interventions based on the CCT framework.

I am 29 years old, Nigerian, and currently based in Lagos. I am not enrolled in a master's programme. I am applying for October 2026 start at the Medical University of Graz in Austria as a parallel track. The Neuroscience Academy Denmark fellowship is my primary target because of its focus on interdisciplinary neuroscience and its support for independent project design.

CHECKLIST

- [ ] Motivation letter, 300-500 words, tailored to Neuroscience Academy Denmark
- [ ] Research statement, 400-600 words, describing CCT model and proposed PhD project
- [ ] Personal statement, 400-600 words, describing background and motivation
- [ ] Curriculum vitae with full publication list, ORCID, GitHub, and platform links
- [ ] Copies of three preprints on OSF and Zenodo with DOIs
- [ ] Copy of review article under review at Neuroscience and Biobehavioral Reviews
- [ ] Copy of co-authored paper under review at Alcohol, Elsevier
- [ ] Academic transcripts from University of Ibadan, B.Pharm, with CGPA and grade equivalence
- [ ] PCN pharmacist license copy
- [ ] Two to three letters of recommendation, ideally from Kent Berridge, Samuel Gershman, or Nathaniel Daw
- [ ] Provisional patent documentation for CCT core architecture
- [ ] English language proficiency certificate if required by Danish Ministry of Education
- [ ] Diploma evaluation request to Danish Ministry of Education for B.Pharm degree equivalence to Danish master's degree

EDITOR NOTES

- Eligibility risk: The programme requires a master's degree equivalent to a Danish master's degree. The applicant holds only a B.Pharm. The diploma must be sent to the Danish Ministry of Education for evaluation. This is a critical gate. The applicant should contact the programme coordinator before the deadline to confirm whether a B.Pharm with research experience and preprints can substitute for a master's degree, or whether conditional admission is possible pending master's enrollment.

- The applicant is not yet enrolled in any master's or PhD programme. The application must clearly state the intended October 2026 start at MUG Graz as a parallel track, and explain how the NAD fellowship would replace or complement that plan.

- The applicant should verify that the three preprints and the review article under review are sufficient to meet the "documented engagement with neuroscience" criterion. If the programme requires published peer-reviewed papers, the applicant may need to submit the Alcohol paper as evidence of peer-reviewed publication, even though it is under review.

- The applicant's age of 29 and graduation year of 2021 may raise questions about the gap between 2021 and 2025. The personal statement should explicitly address this period: the clinical pharmacy work, the research assistant roles, and the independent development of the CCT model. The current draft covers this but should be checked for completeness.

- The applicant should confirm that the B.Pharm from University of Ibadan is recognized as equivalent to a Danish master's degree by the Danish Ministry of Education. If not, the applicant may need to enroll in a master's programme first, which would change the application strategy.

AI Draft — 16 PhD Fellowships - Neuroscience Academy Denmark